Repaglinide (cas 108157-52-4)☆
-
Add time:08/26/2019 Source:sciencedirect.com
Repaglinide is a nonsulfonylurea, oral hypoglycemic agent used in the treatment of type 2 diabetes mellitus. It stimulates insulin secretion by binding to the sulfonylurea receptor (SUR1) subunit of the KATP channel, thus blocking the channel, resulting in depolarization of the beta-cell membrane, and a consequent influx of Ca2 +. It is fast acting, with a short duration of action and is administered before each meal.
We also recommend Trading Suppliers and Manufacturers of Repaglinide (cas 108157-52-4). Pls Click Website Link as below: cas 108157-52-4 suppliers
Prev:Conformational flexibility and packing plausibility of Repaglinide (cas 108157-52-4) polymorphs
Next:Conformation of Repaglinide (cas 108157-52-4): A solvent dependent structure) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- A floating-type dosage form of Repaglinide (cas 108157-52-4) in polycarbonate microspheres08/31/2019
- Development of Repaglinide (cas 108157-52-4) microspheres using novel acetylated starches of bitter and Chinese yams as polymers08/30/2019
- Dual crosslinked pectin–alginate network as sustained release hydrophilic matrix for Repaglinide (cas 108157-52-4)08/29/2019
- The first insight into the supramolecular structures of popular drug Repaglinide (cas 108157-52-4): Focus on intermolecular interactions in antidiabetic agents08/28/2019
- Conformation of Repaglinide (cas 108157-52-4): A solvent dependent structure08/27/2019
- Conformational flexibility and packing plausibility of Repaglinide (cas 108157-52-4) polymorphs08/25/2019
- Identification of Repaglinide (cas 108157-52-4) as a therapeutic drug for glioblastoma multiforme08/24/2019
- Endocrine pharmacologyCharacteristics of Repaglinide (cas 108157-52-4) effects on insulin secretion08/23/2019
- ArticleThe Structural Basis for the Binding of Repaglinide (cas 108157-52-4) to the Pancreatic KATP Channel08/22/2019
